Prevalence of celiac disease and related antibodies in patients diagnosed with irritable bowel syndrome according to the Rome III criteria. A case-control study.

Autor: Sánchez-Vargas LA; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico.; Doctorate in Biomedical Sciences, Universidad Veracruzana, Xalapa, Veracruz, Mexico., Thomas-Dupont P; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico.; Doctorate in Biomedical Sciences, Universidad Veracruzana, Xalapa, Veracruz, Mexico., Torres-Aguilera M; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico., Azamar-Jacome AA; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico., Ramírez-Ceervanes KL; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico., Aedo-Garcés MR; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico., Meixueiro-Daza A; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico., Roesch-Dietlen F; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico.; Faculty of Medicine Miguel Alemán Valdés, Veracruz, Veracruz, Mexico., Grube-Pagola P; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico., Vivanco-Cid H; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico., Remes-Troche JM; Gastrointestinal Motility and Digestive Physiology Laboratory, Medical and Biological Research Institute of the Universidad Veracruzana, Veracruz, Veracruz, Mexico.; Faculty of Medicine Miguel Alemán Valdés, Veracruz, Veracruz, Mexico.
Jazyk: angličtina
Zdroj: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society [Neurogastroenterol Motil] 2016 Jul; Vol. 28 (7), pp. 994-1000. Date of Electronic Publication: 2016 Feb 23.
DOI: 10.1111/nmo.12799
Abstrakt: Background: The cost-effectiveness for screening for celiac disease (CD) in patients with irritable bowel syndrome (IBS), specifically in the diarrhea (IBS-D) subtype, is beneficial if the prevalence is >1%. However, recent studies have shown controversial results. In this large case-control study, our aim was to determine the prevalence of CD and a panel of related antibodies in patients diagnosed with IBS.
Materials and Methods: Four hundred IBS patients (Rome III) and 400 asymptomatic healthy controls were prospectively evaluated using antihuman tissue transglutaminase (h-tTG IgA) and deamidated gliadin peptide antibodies (DGP II IgA and DGP II IgG). Duodenal biopsy was performed on the patients that were positive for the h-tTG IgA and/or DGP II IgG antibodies.
Results: The mean age of the population was 44.47 ± 18.01 years and 335 (82%) of the subjects were women. Twenty-one patients and six controls had at least one positive test for CD (5.25% VS 1.5%, p = 0.003, OR 3.63 [95% CI 1.4-9.11]). Eighteen patients were positive for h-tTG and/or DGP-II IgG. Histologic confirmation of CD was 2.5% in the IBS patients vs 0.5% in the controls (p = 0.04, OR 5.21). The IBS-D subtype had the highest prevalence for serological positivity (12.7%).
Conclusions: Up to 5.2% of the patients with IBS according to the Rome III criteria were positive for at least one of the CD-related antibodies and 2.5% had biopsy-confirmed CD. Therefore, in our population, screening for CD in subjects with IBS appears to be a reasonable strategy, especially in the IBS-D subgroup.
(© 2016 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje